These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19070809)

  • 21. Advanced renal cell carcinoma: what to do after first line antiangiogenic therapy?
    Soulières D
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):153-6. PubMed ID: 19512932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
    Ansari J; Fatima A; Chaudhri S; Bhatt RI; Wallace M; James ND
    Onkologie; 2009 Feb; 32(1-2):44-6. PubMed ID: 19209019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
    Carver BS
    J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
    [No Abstract]   [Full Text] [Related]  

  • 24. Unexpected 10 years complete remission after cortisone mono-therapy in metastatic renal cell carcinoma.
    Christophersen AO; Lie AK; Fosså SD
    Acta Oncol; 2006; 45(2):226-8. PubMed ID: 16546876
    [No Abstract]   [Full Text] [Related]  

  • 25. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of metastatic renal cell carcinoma: current trends.
    Mohammed A; Shergill I; Little B
    Expert Rev Mol Diagn; 2009 Jan; 9(1):75-83. PubMed ID: 19099350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination targeted therapy in advanced renal cell carcinoma.
    Sosman J; Puzanov I
    Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in central and peripheral blood pressure parameters during antiangiogenic treatment of metastatic renal cell carcinoma.
    Lipski D; Uruski P; Tomczak P; Adamiak J; Ramlau R; Tykarski A
    Pol Arch Intern Med; 2019 Dec; 129(12):942-944. PubMed ID: 31625532
    [No Abstract]   [Full Text] [Related]  

  • 29. New therapies after failure of angiogenesis inhibitors.
    Escudier B
    Clin Adv Hematol Oncol; 2009 Aug; 7(8):512-4. PubMed ID: 19927977
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical response of renal cell carcinoma to dexamethasone.
    Schöffski P; Wolter P; Vandenborre K; Haustermans K
    Cancer Invest; 2009 Jun; 27(5):529-32. PubMed ID: 19340657
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hypertension and palmar plantar erythroderma. Management of adverse events of angiogenetic inhibitors in the treatment of renal cell carcinoma].
    Rolfes N; Lümmen G
    Urologe A; 2011 Nov; 50(11):1387-91. PubMed ID: 21800197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic renal cell carcinoma: many treatment options, one patient.
    Rini BI
    J Clin Oncol; 2009 Jul; 27(19):3225-34. PubMed ID: 19470934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seminal vesicle metastasis of renal cell carcinoma.
    Matsuzaki K; Yasunaga Y; Fukuda S; Oka T
    Urology; 2009 Nov; 74(5):1017-8. PubMed ID: 19589576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroid metastasis of clear cell renal carcinoma: Report of a case.
    Rizzo M; Rossi RT; Bonaffini O; Scisca C; Sindoni A; Altavilla G; Benvenga S
    Diagn Cytopathol; 2009 Oct; 37(10):759-62. PubMed ID: 19530097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors.
    Dirix LY; Maes H; Sweldens C
    Ann Oncol; 2007 Jun; 18(6):1121-2. PubMed ID: 17586755
    [No Abstract]   [Full Text] [Related]  

  • 36. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.
    Wood CG; Margulis V
    Cancer; 2009 May; 115(10 Suppl):2355-60. PubMed ID: 19402066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Late pancreatic metastasis from primary Grawitz tumor--surgical management].
    Ion D; Sajin M; Copcă N; Pariza G; Mavrodin CI; Ciurea M
    Chirurgia (Bucur); 2009; 104(1):105-7. PubMed ID: 19388577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
    Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
    J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
    Yalcin M; Bharali DJ; Lansing L; Dyskin E; Mousa SS; Hercbergs A; Davis FB; Davis PJ; Mousa SA
    Anticancer Res; 2009 Oct; 29(10):3825-31. PubMed ID: 19846915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. For: Radical nephrectomy in the setting of metastatic renal cell cancer: proceed judiciously.
    Aron M; Gill IS
    J Urol; 2009 Sep; 182(3):832-3. PubMed ID: 19643447
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.